[Skip to Content]
[Skip to Content Landing]
February 1972

Inhibition of Experimental Mammary CarcinomaAutologous Intrasplenic Ovarian Transplant

Author Affiliations

From the Department of Surgery and the Fels Research Institute of Temple University Health Sciences Center, Philadelphia.

Arch Surg. 1972;104(2):206-208. doi:10.1001/archsurg.1972.04180020086017

Intrasplenic ovarian autotransplantation is associated with significant inhibition of 7,12-dimethylbenz (a) anthracene-produced breast carcinoma in the rat. The mechanism of this inhibition may be related to the position of the transplanted ovary within the portal venous system, allowing initial drainage of ovarian venous efflux through the liver. Hepatic alteration of ovarian hormones could result in changes in hormone concentration within the mammary gland, and this may represent the mechanism of inhibition of tumorigenesis. End-to-side portacaval shunt done simultaneously with intrasplenic ovarian transplantation is also associated with significant inhibition of experimental breast carcinoma. The previously observed inhibition of experimental breast carcinoma by end-to-side portacaval shunt alone has been reconfirmed.